Overview
To evaluate whether rimegepant improves acute vestibular symptoms and accompanying discomforts in patients with vestibular migraine.
Eligibility
Inclusion Criteria:
- Age 18-60 years, male or female.
- Diagnosis of vestibular migraine according to the Bárány Society criteria.
- ≥4 episodes of characteristic vestibular symptoms in the past year, each of moderate to severe intensity and lasting \>2 hours (without intervention).
- Signed informed consent obtained from the participant.
Exclusion Criteria:
- Presence of other disorders causing acute vestibular symptoms (e.g., Ménière's disease, otitis media).
- Coexisting non-vertiginous dizziness (e.g., dizziness due to panic disorder), unless the patient can clearly distinguish these episodes from vestibular-migraine attacks.
- Severe hepatic dysfunction (ALT and/or AST \>3× upper limit of normal) or renal impairment (creatinine clearance \<30 mL/min).
- Severe cardiovascular or cerebrovascular disease.
- Alcohol abuse or substance abuse.
- Known pregnancy or lactation, or a positive pregnancy test prior to randomization.
- Contraindication or hypersensitivity to any medications used in the study.
- Initiation or dose adjustment of any preventive migraine therapy within 3 months prior to study drug administration.
- Use of any other anti-vertigo or analgesic medication within 6 hours before study drug administration.
- Participation in another interventional clinical study that could affect outcome assessment.
- Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study or poses significant risk.
